Placeholder Abstract Submission Guidelines for Clinical Trials

All clinical trials abstracts must be submitted by January 8, 2024. A placeholder for a clinical trials abstract may be submitted to one of the Clinical Trials Placeholder categories (PL) only if the trial is ongoing, and final data are not available by the January 8 submission deadline but are expected to be collected between January 8 and February 6.

The placeholder abstract must be submitted by January 8, 2024.

Please note:

- Placeholder abstracts may be submitted for any phase trial (placeholder abstracts are not permitted for Trials in Progress.)
- A placeholder abstract should only be submitted if final data from an ongoing trial are not available by the January 8 deadline.
- Placeholder abstracts must be submitted to the appropriate PL category by January 8 and should include a tentative title, the full author list and disclosures, background information, and materials and methods. A description of any data that will be submitted with the final abstract should be added, including primary clinical endpoints, and dates and plans for the data analysis.
- A request and instructions will be sent to the submitting author to submit the updated final abstract by February 6.
- The Clinical Trials Committee will assess the placeholder abstract submission and then conduct a rapid review of the final abstract.

Placeholder Abstract Categories:

- PL02 Phase 0 Clinical Trials
- PL03 First-in-Human Phase I Clinical Trials
- PL04 Phase I Adult Clinical Trials
- PL05 Phase II Adult Clinical Trials
- PL06 Phase III Adult Clinical Trials
- PL07 Phase I, II, or III Clinical Trials in Pediatric Cancer
  - Phase I Clinical Trials in Pediatric Cancer
  - Phase II Clinical Trials in Pediatric Cancer
  - Phase III Clinical Trials in Pediatric Cancer

For additional information on clinical trial abstract submissions, view the Spotlight on Clinical Trials tab on the meeting website: AACR.org/AACR2024